Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for FBLG is 26.49M, and at present, short sellers hold a 9.43% of that float. On January 01, 2025, the average trading volume of FBLG was 159.25K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FBLG) stock’s latest price update
FibroBiologics Inc (NASDAQ: FBLG)’s stock price has dropped by -10.71 in relation to previous closing price of 2.24. Nevertheless, the company has seen a loss of -4.76% in its stock price over the last five trading days. globenewswire.com reported 2024-12-30 that HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has closed the second $5 million tranche of the previously announced Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.
FBLG’s Market Performance
FibroBiologics Inc (FBLG) has seen a -4.76% fall in stock performance for the week, with a -23.66% decline in the past month and a -31.03% plunge in the past quarter. The volatility ratio for the week is 12.32%, and the volatility levels for the past 30 days are at 11.63% for FBLG. The simple moving average for the past 20 days is -11.97% for FBLG’s stock, with a -63.21% simple moving average for the past 200 days.
Analysts’ Opinion of FBLG
Many brokerage firms have already submitted their reports for FBLG stocks, with Rodman & Renshaw repeating the rating for FBLG by listing it as a “Buy.” The predicted price for FBLG in the upcoming period, according to Rodman & Renshaw is $12 based on the research report published on December 12, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see FBLG reach a price target of $12. The rating they have provided for FBLG stocks is “Buy” according to the report published on October 30th, 2024.
Maxim Group gave a rating of “Buy” to FBLG, setting the target price at $12 in the report published on September 24th of the previous year.
FBLG Trading at -24.39% from the 50-Day Moving Average
After a stumble in the market that brought FBLG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.36% of loss for the given period.
Volatility was left at 11.63%, however, over the last 30 days, the volatility rate increased by 12.32%, as shares sank -26.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.00% lower at present.
During the last 5 trading sessions, FBLG fell by -4.76%, which changed the moving average for the period of 200-days by -80.08% in comparison to the 20-day moving average, which settled at $2.27. In addition, FibroBiologics Inc saw -93.13% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FBLG starting from O’HEERON PETE, who purchase 8,500 shares at the price of $1.91 back on Aug 12 ’24. After this action, O’HEERON PETE now owns 6,056,647 shares of FibroBiologics Inc, valued at $16,269 using the latest closing price.
Khoja Hamid, the Chief Scientific Officer of FibroBiologics Inc, purchase 10,000 shares at $1.90 during a trade that took place back on Aug 12 ’24, which means that Khoja Hamid is holding 11,250 shares at $19,000 based on the most recent closing price.
Stock Fundamentals for FBLG
The total capital return value is set at -3.3. Equity return is now at value -267.86, with -149.60 for asset returns.
Based on FibroBiologics Inc (FBLG), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -90.69. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -833.73.
Currently, EBITDA for the company is -15.9 million with net debt to EBITDA at 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.23.
Conclusion
To sum up, FibroBiologics Inc (FBLG) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
